Canada’s first evidence-based medical cannabis formulary launches today
March 20, 2019 09:15 ET
|
Reformulary Group
TORONTO, March 20, 2019 (GLOBE NEWSWIRE) -- Reformulary Group, a Canadian healthcare technology company, today announced the launch of Cannabis Standard™ – the first evidence-based medical cannabis...
New report: Are prescriptions contributing to the opioid crisis?
January 22, 2019 09:00 ET
|
Reformulary Group
TORONTO, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Reformulary Group, a Canadian healthcare technology company, today released a report on opioid prescribing in Canada. The report analyzes the data of over...
Starseed joins Cannabis Standard™ for Canadians, employers, physicians
September 12, 2018 09:24 ET
|
Reformulary Group
TORONTO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Reformulary Group, Canada’s leading independent drug plan management company, today announced it has signed Licensed Producer (LP) Starseed Medicinal Inc....
Reformulary Group signs Aphria to provide medical cannabis for employer plans
May 29, 2018 14:12 ET
|
Reformulary Group
TORONTO, May 29, 2018 (GLOBE NEWSWIRE) -- Reformulary Group, Canada’s leading, independent drug plan management company, today announced it has signed Leamington, Ontario-based cannabis producer...
Reformulary Group signs MedReleaf as first Licensed Producer for new medical cannabis formulary
May 22, 2018 11:40 ET
|
Reformulary Group
TORONTO, May 22, 2018 (GLOBE NEWSWIRE) -- Reformulary Group, Canada’s leading, independent drug plan management company, today announced it has signed MedReleaf as its first Licensed Producer of...
Reformulary Group’s prescription drug tool receives TELUS Outstanding Product Award
May 16, 2018 13:22 ET
|
Reformulary Group
TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- Last night at the 33rd annual Canadian Advanced Technology Alliance Leadership Awards Gala, Reformulary Group received the TELUS Outstanding Product...
Expert group to review evidence for use of medical cannabis for employer plans
May 16, 2018 12:53 ET
|
Reformulary Group
TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- Today, Reformulary Group, Canada’s leading, independent drug plan management company, announced its Cannabis Formulary Committee, which will review the best...